ASX Announcement – Corporate Updates for Optiscan

Optiscan ASX Announcement Company Update Highlights:

  • Optiscan expects additional cash receipts including from Carl Zeiss Meditec for in excess of $200k.
  • Total cash receipts from end of February till end of April are expected to exceed $900k.
  • Leading medical journal, Nature Biomedical Engineering, publishes study led by Memorial Sloan Kettering Cancer Centre researchers confirming the potential for Optiscan technology to be used for “…intraoperative, PARPi-FL-based in vivo imaging without tissue excision.”

To read the full announcement, click here.

Register Interest

About Optiscan

OptiScan (ASX:OIL) is an Australian listed company and a pioneer in the development and application of endomicroscopic imaging technologies for medical markets.   Our multi-patented confocal imaging technology can be used for both cancer screening and tumour margin detection in cancer surgery.  Our device enables real-time, in vivo imaging at the cellular level in clinical applications, providing a “digital” biopsy.  The benefits of this “digital” biopsy include monitoring of early stage disease, earlier identification of pre-cancer and the potential to reduce the time doctors, patients and operating theatres are required to wait for pathology results, the number of repeat surgeries and actual biopsies required.

Register Interest